Antiretroviral therapy coverage in Peru
Peru: Antiretroviral therapy coverage was 80.0% in 2024. ◆ Volatile
Antiretroviral therapy coverage in Peru, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
In 2024, antiretroviral therapy coverage in Peru stood at 80.0%. That is the highest value across all 25 years on record.
That represents a change of up 5.3% on the previous year and up 81.8% over ten years.
Over the whole period, antiretroviral therapy coverage in Peru peaked at 80.0% in 2024 and was at its lowest, 0.0%, in 2000.
That places Peru 51st out of 143 countries with data for 2024, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Peru, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 2.0% | — |
| 2003 | 3.0% | +50.0% |
| 2004 | 2.0% | -33.3% |
| 2005 | 6.0% | +200.0% |
| 2006 | 9.0% | +50.0% |
| 2007 | 14.0% | +55.6% |
| 2008 | 16.0% | +14.3% |
| 2009 | 23.0% | +43.8% |
| 2010 | 30.0% | +30.4% |
| 2011 | 32.0% | +6.7% |
| 2012 | 39.0% | +21.9% |
| 2013 | 39.0% | +0.0% |
| 2014 | 44.0% | +12.8% |
| 2015 | 44.0% | +0.0% |
| 2016 | 52.0% | +18.2% |
| 2017 | 56.0% | +7.7% |
| 2018 | 62.0% | +10.7% |
| 2019 | 68.0% | +9.7% |
| 2020 | 69.0% | +1.5% |
| 2021 | 73.0% | +5.8% |
| 2022 | 77.0% | +5.5% |
| 2023 | 76.0% | -1.3% |
| 2024 | 80.0% | +5.3% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 7.5% | 0.0% | 23.0% | 10 |
| 2010s | 46.6% | 30.0% | 68.0% | 10 |
| 2020s | 75.0% | 69.0% | 80.0% | 5 |
Countries ranked near Peru
- 49 South Africa 81.0% compare
- 49 Tajikistan 81.0% compare
- 51 Cape Verde 80.0% compare
- 53 Argentina 79.0% compare
- 53 Guinea-Bissau 79.0% compare
- 53 Lebanon 79.0% compare
- 53 Senegal 79.0% compare
More health data for Peru
- Un projection of annual infant deaths, annual growth rate -1.88 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5045 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,235 deaths per 1,000 people (2090)
- Number of infants who die before age 1 782 deaths (2100)
- Population ages 15-19, male, annual growth rate -0.1886 % change on previous year (2025)
- Population ages 15-19, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 15-19, male, per capita 0.0424 units per person (2025)
- Population ages 20-24, female, annual growth rate 0.4607 % change on previous year (2025)
- Population ages 20-24, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 20-24, female, per capita 0.0404 units per person (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Peru?
- Antiretroviral therapy coverage in Peru was 80.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Peru?
- The highest recorded value was 80.0% in 2024.
- What is the lowest antiretroviral therapy coverage recorded in Peru?
- The lowest recorded value was 0.0% in 2000.
- How does Peru rank for antiretroviral therapy coverage?
- Peru ranks 51st out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Peru?
- Over the last ten years it is up 81.8%. The long-run trend across the full record is volatile.
- Where does this Peru data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.